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Abstract
Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a
prospective study to investigate whether constitutive genetic background might affect response to therapy. In
a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5epoly-
morphism-based genetic score could be used to identify patients with different risks of progression and death.
Introduction: Approximately 50% of locally advanced or metastatic breast cancer (MBC) patients treated with first-
line exemestane do not show objective response and currently there are no reliable biomarkers to predict the
outcome of patients using this therapy. The constitutive genetic background might be responsible for differences inThis work was supported by Pfizer Italia (grant number: CUP: J31J06000270007).
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report for publication.
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Genetic Risk Score to Predict Exemestane Outcomethe outcome of exemestane-treated patients. We designed a prospective study to investigate the role of germ line
polymorphisms as biomarkers of survival. Patients and Methods: Three hundred two locally advanced or MBC
patients treated with first-line exemestane were genotyped for 74 germ line polymorphisms in 39 candidate genes
involved in drug activity, hormone balance, DNA replication and repair, and cell signaling pathways. Associations with
progression-free survival (PFS) and overall survival (OS) were tested with multivariate Cox regression. Bootstrap
resampling was used as an internal assessment of results reproducibility. Results: Cytochrome P450 19A1-
rs10046TC/CC, solute carrier organic anion transporter 1B1-rs4149056TT, adenosine triphosphate binding cassette
subfamily G member 2-rs2046134GG, fibroblast growth factor receptore4-rs351855TT, and X-ray repair cross
complementing 3-rs861539TT were significantly associated with PFS and then combined into a risk score (0-1, 2, 3, or
4-6 risk points). Patients with the highest risk score (4-6 risk points) compared with ones with the lowest score (0-1 risk
points) had a median PFS of 10 months versus 26.3 months (adjusted hazard ratio [AdjHR], 3.12 [95% confidence
interval (CI), 2.18-4.48]; P < .001) and a median OS of 38.9 months versus 63.0 months (AdjHR, 2.41 [95% CI, 1.22-
4.79], P ¼ .012), respectively. Conclusion: In this study we defined a score including 5 polymorphisms to stratify
patients for PFS and OS. This score, if validated, might be translated to personalize locally advanced or MBC patient
treatment and management.
Clinical Breast Cancer, Vol. -, No. -, 1-9 ª 2018 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite that personalized medicine has assumed a crucial role in
recent years, pharmacogenetic investigations, aiming at identifying
predictive/prognostic biomarkers, usually represent only secondary
aims in clinical trials. In this scenario, setting up prospective studies,
designed ad hoc to investigate the effect of genetic variants in
candidate genes and pathways, could be an effective strategy to
produce reliable and clinically useful results.
Exemestane is a steroidal aromatase inhibitor (AI) for the
treatment of postmenopausal patients affected by hormone
receptor-positive (HRþ) breast cancer (BC). It is registered for the
adjuvant and the advanced settings for the treatment of locally
advanced or metastatic BC (MBC).1 Exemestane has shown efficacy
in several clinical trials,2-4 but almost the 50% of patients, after an
initial benefit, experience disease progression.4-6 Unfortunately,
there are still no biomarkers to predict the outcome of exemestane-
treated patients.7-9
A great effort has been done in the past years to identify germ line
variants as predictive and/or prognostic biomarkers in patients
treated with AIs, including exemestane.10-13 Polymorphisms in
genes affecting either the activity or the expression of the drug target
(aromatase, cytochrome P450 19A1 [CYP19A1]), or influencing
drug/hormone activity (CYP17A1,14,15 estrogen receptor 1
[ESR1],10,16 ESR2,10 PR/SET domain 2 [PRDM2]17), metabolism
(Catechol-O-methyltransferase [COMT],14,15 CYP1B1,15 uridine
diphosphate [UDP] glucuronosyltransferase family 1 member A1
[UGT1A1],18 CYP3A4,19,20 CYP3A519), or transport (adenosine
triphosphate [ATP] binding cassette [ABC],18 and solute carrier
organic anion [SLCO] transporters21) have been investigated as
potential predictive or prognostic biomarkers of efficacy.22
In this context, another mechanism of interest is the DNA repair
pathway, that is deregulated in BC. The deficiency in DNA repair
capacity is considered a hallmark of breast carcinogenesis.23 A recent
report on the outcome of patients treated with AIs has highlightednical Breast Cancer Month 2018somatic mutations on genes involved in DNA replication, repair,
cell cycle, and tumor protein p53 signaling pathways. These somatic
mutations were associated with AI resistance.24 However, the role of
the germ line variants in these pathways has not been investigated.
To assess the clinical value of germ line polymorphisms as potential
indicators of exemestane outcome, we performed a prospective
multicenter study, specifically designed to investigate the role of germ
line DNA variants to predict survival in patients treated with
exemestane. This study was carried out on 302HRþ locally advanced
or MBC patients treated with exemestane as first-line hormonal
therapy. Seventy-four polymorphisms in 39 candidate genes involved
in drug activity, hormone balance, DNA replication and repair, and
cell signaling pathways were investigated to identify biomarkers of
progression-free survival (PFS) and overall survival (OS).
Patients and Methods
Patients
This prospective study involved 23 Italian centers. All procedures
were approved by the ethics committee of the sponsoring center,
National Cancer Institute Centro di Riferimento Oncologico di
Aviano (protocol number 1003/D; November 11, 2005), and in-
vestigations were performed in accordance with Declaration of
Helsinki. HRþ locally advanced or MBC postmenopausal patients
treated with exemestane were enrolled from 2007 to 2012. Patients
signed a written informed consent for the purpose of this research.
Eligibility criteria included: blood sample availability, measurable
and nontarget lesions defined according to Response Evaluation
Criteria In Solid Tumors version 1 (RECIST) criteria, Eastern
Cooperative Oncology Group performance status 0 to 2, absolute
neutrophil count 1500/mL, platelets 100,000/mL,
hemoglobin 9.0 g/dL, and HER2-negative. Exclusion criteria
were: previous exemestane treatment or other hormonal therapy in
the advanced/metastatic setting, brain metastasis, serious infectious
disease, serious functional alteration of visceral and metabolic
Table 1 Patient Clinical and Demographic Characteristics
Patient and
Tumor
Characteristic Value
PFS HR,
P
OS HR,
P
Total, n 302
Age, Years
Median (range) 71 (35-93)
<60, n (%) 58 (19.2) Ref Ref
61-70, n (%) 88 (29.1) NS NS
71-80, n (%) 108 (35.8) 0.69, .051 NS
>80, n (%) 48 (15.9) 0.44, .001 NS
Sex, n (%)
Female 301 (99.6)
Male 1 (0.4)
Stage at Diagnosis,
n (%)
I-II 130 (43.0) Ref Ref
III-IV 170 (56.3) 1.38, .015 2.04, .001
Unknown 2 (0.7)
Dominant Metastatic
Site, n (%)
Visceral 183 (60.6)
Bonea 102 (33.8)a
Soft tissue 17 (5.6)
Liver Involvement
No 257 (85.1) Ref Ref
Yes 45 (14.9) 2.49, .001 1.83, .008
Metastatic Sites at Recruitment, n (%)
1 91 (30.1)
2-3 157 (52.0)
4-5 54 (17.9)
ER/PgR Status
ERþ/PgRþ 257 (85.1)
ERþ/PgR- 44 (14.6)
ER/PgRþ 1 (0.3)
ER Expression, n (%)
0-50% 100 (33.1)
51-75% 49 (16.2)
76-100% 153 (50.7)
PgR Expression,
n (%)
0-10% 87 (28.8) Ref Ref
11-100% 215 (71.2) 0.58, .001 0.41, .001
Surgery, n (%)
No 60 (19.9) Ref Ref
Yes 242 (80.1) NS 0.44, .001
Previous
Chemotherapy, n (%)
No 138 (45.7) Ref Ref
Yes 164 (54.3) 1.56, .001 NS
Neo- or adjuvant 124 (41.1)
First-lineb 40 (13.2)b
Table 1 Continued
Patient and
Tumor
Characteristic Value
PFS HR,
P
OS HR,
P
Previous Hormone
Therapy, n (%)
No 140 (46.4) Ref Ref
Adjuvant tamoxifen 98 (32.5) NS NS
Adjuvant AIc 64 (21.1)c 1.49, .018 NS
PFS
Progression, n (%) 238 (78.8)
Median PFS (range) 15.4 (0.8-115.6)
OS
Deaths, n (%) 141 (46.7)
Median OS (range) 26.8 (1.5-152.6)
Significant results are shown in bold text.
Abbreviations: AI ¼ aromatase inhibitor; ER ¼ estrogen receptor; HR ¼ hazard ratio; NS ¼ not
significant; OS ¼ overall survival; PFS ¼ progression-free survival; PgR ¼ progesterone re-
ceptor; Ref ¼ reference category.
aTen of 302 patients had bone and soft tissue lesions.
bSeventeen patients also underwent neo- or adjuvant therapy.
cThirty-one patients have also taken tamoxifen.
Sara Gagno et aldisease, radiotherapy or major surgery within 4 weeks from start of
exemestane treatment, previous or concomitant neoplasm
(excluding in situ cervical cancer), and inability to attend periodical
clinical and/or radiological evaluations.
Clinical data were collected on case report forms. Details on
primitive tumor, previous treatments, exemestane therapy, and
follow-up information are reported in Table 1. Data were reviewed
by an internal board and stored in a database. Hormone receptor
status was assessed according to the 2010 American Society of
Clinical Oncology guidelines.
Data Statement
The data set generated and analyzed during the current study is
not publicly available because the biological material and clinical
data were collected from patients only for the purposes of this study.
However, the data set is available from the corresponding author
upon reasonable request.
Efficacy Evaluation
Patients were treated with 25 mg of daily oral exemestane. Effi-
cacy evaluation occurred every 8 weeks for at least 24 weeks ac-
cording to RECIST criteria. Treatment was continued until disease
progression, unacceptable toxicity, death, or consent withdrawal.
Progression-free survival was defined as the time between treat-
ment initiation and tumor progression or death from any cause. OS
was defined as the time between treatment initiation and death from
any cause. Patients lost at follow-up were censored at the time of
their last follow-up.
Gene Variants and Genotyping
Genes and polymorphisms of interest were selected upon litera-
ture analysis on the basis of association with cancer, BC, and AIsClinical Breast Cancer Month 2018 - 3
Figure 1 Study Flow Chart. Three Hundred Two Patients Were
Enrolled in the Period From 2007 to 2012. Among
Them, at Least 298 Were Genotyped for All of the 74
Polymorphisms Investigated. All of the
Polymorphisms Were Tested for Association With
Progression-Free Survival (PFS) and Overall Survival
(OS). Cox Multivariate Regression and Bootstrap
Analyses Highlighted 5 Polymorphisms as
Significantly Associated With PFS. None of the Tested
Polymorphisms Was Significantly Associated With
OS. The Risk Score Obtained From the Combination
of These 5 Polymorphisms Was Subsequently Tested
for Association With PFS and OS, Showing a Better
Stratification Ability Than the Single Polymorphisms
for PFS and a Trend for Association With OS
302 Paents eligible for the genotyping of 74 
polymorphisms
End points: 
PFS and OS
5 Polymorphisms associated with PFS
(CYP19A1-rs10046, SLCO1B1-rs4149056, 
ABCG2-rs2046134, FGFR4-rs351855, and XRCC3-rs861539)
Mulvariate analysis 
and
Bootstrap analysis
Idenficaon of risk 
score
Combinaon
Best straficaon for PFS and 
OS
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4 - Clioutcome. Moreover, to assess the involvement of selected genes into
pathways of interest, each gene was searched in the Gene database of
the National Center for Biotechnology Information . Genes and
polymorphisms investigated are listed in Supplemental Table 1 in
the online version. Linkage disequilibrium between variants was
assessed using the Genome Variation Server (http://gvs.gs.
washington.edu/GVS150/). A 3-mL blood sample was obtained
from each patient before the first administration of exemestane.
Genomic DNA was automatically extracted with BioRobot EZ1 kit
(Qiagen SPA, Milan, Italy).
Polymorphisms were genotyped with Automated Fragment
Analysis on Genetic Analyzer ABI PRISM 3100 (Applied
Biosystems, Foster City, CA), TaqMan Assays on a 7500 Real-Timenical Breast Cancer Month 2018PCR System (Applied Biosystems), PSQ96 MA Pyrosequencing
(Biotage AB, Uppsala, Sweden), or a custom-designed Illumina
GoldenGate Assay on a BeadXpress Reader (Illumina, San Diego,
CA). Analyses were performed according to manufacturer’s
instructions including negative and positive controls. Twelve poly-
morphisms analyzed using the GoldenGate Assay were also analyzed
using TaqMan (Applied Biosystems) or Pyrosequencing (Biotage
AB) as control.
Statistical Analyses
Progression-free survival and OS were assessed using multivariate
Cox regression; clinical variables were included in the model if
associated with a P value < .05 at univariate analysis, with one of
the outcomes considered (Table 1). Proportional hazards assump-
tion was assessed using Schoenfeld residuals. All tests of statistical
significance were 2-sided and medians were reported with their
relative minimum and maximum range or 95% confidence interval
(CI). Robust standard errors were calculated to take into account
the possible lack of independence between patients from the same
hospital.25 Additive, dominant, and recessive genetic models were
evaluated, and the most statistically significant model for each
polymorphism was selected. Ninety-five percent CIs and P values
were estimated using a bootstrap resampling technique with 1000
replications. A P value cutoff of .05 after bootstrapping was
considered to be statistically significant. Unadjusted differences in
PFS and OS according to genotypes were assessed using
KaplaneMeier estimates and the statistical significance using the log
rank test. Genotypes individually associated with a higher risk of
progression or not showing a protective effect were used to generate
a genetic risk score. All the analyses were performed using STATA
version 13 software (StataCorp LLC, Cary, NC).
Results
Patients and Clinical Outcome
Three hundred two patients with locally advanced or MBC
treated with first-line exemestane were enrolled in this prospective
pharmacogenetic study (Figure 1). All of the subjects were of
Caucasian origin (self-reported). Patient median age was 71 (range,
35-93) years and the median follow-up was 35 (range, 2-153)
months. The median treatment duration was 11.7 months (range,
0.7-84.8). Patients, tumor, and treatment characteristics are
summarized in Table 1.
Genetic Analyses
Seventy-four polymorphisms in 39 genes involved in drug
activity, hormone balance, DNA replication and repair, and cell
signaling pathways were identified. The allele frequencies are
reported in Supplemental Table 1 in the online version and were
consistent with those previously reported (https://www.ncbi.nlm.
nih.gov/snp). As a test for genotyping quality control, genotype
data were obtained using 2 different techniques in 247 patients for
CYP19A1-rs4646, CYP3A5-rs776746, COMT-rs4680,
ESR1-rs2234693, ESR2-rs1256049, ESR2-rs4986938, CYP17A1-
rs743572, CYP19A1-rs700519, CYP19A1-rs10046, CYP3A4-
rs2740574, and PRDM2-rs2308040 variants. These analyses had a
complete concordance rate (100%).
Table 2 Variants Significantly Associated With PFS
Gene rsID Variant Model AdjHR (95% CI) P
95% CI
Bootstrapped Value
P Bootstrapped
Value
ABCG2 rs2046134 G>A Dominant 0.62 (0.41-0.93) .020 0.39-0.97 .038
CYP19A1 rs10046 T>C Additive 1.15 (1.02-1.29) .021 1.01-1.31 .038
SLCO1B1 rs4149056 T>C Dominant 0.54 (0.41-0.71) .000 0.36-0.80 .002
FGFR4 rs351855 C>T Recessive 1.85 (1.15-2.99) .011 1.03-3.34 .039
XRCC3 rs861539 C>T Recessive 1.72 (1.15-2.57) .008 1.02-2.90 .043
The results were adjusted for the clinical variables significantly associated with PFS and OS. 95% CI and P values were estimated using the bootstrap resampling method by drawing 1000 samples
from the original data set.
Abbreviations: AdjHR ¼ adjusted hazard ratio; OS ¼ overall survival; PFS ¼ progression-free survival; rsID ¼ reference single-nucleotide polymorphism identification number.
Sara Gagno et alProgression-Free Survival and OS Analyses
The following clinical variables were associated with either PFS
and/or OS and were used as covariates for multivariate analyses: age,
stage at diagnosis, progesterone receptor expression, liver involve-
ment, surgery, chemotherapy, and adjuvant hormonal therapy
(Table 1).
In multivariate analysis, 5 polymorphisms were significantly
associated with PFS: CYP19A1-rs10046, solute carrier organic
anion transporter 1B1 (SLCO1B1)-rs4149056, ATP binding
cassette subfamily G member 2 (ABCG2)-rs2046134, fibroblast
growth factor receptore4 (FGFR4)-rs351855, and X-ray repair
cross complementing 3 (XRCC3)-rs861539 (Table 2, Figure 2).
In particular, the variant C allele of CYP19A1-rs10046, on the
aromatase gene, was significantly associated with an increased risk of
progression (additive model, adjusted hazard ratio [AdjHR], 1.15;
bootstrapped 95% confidence interval [95%CIbootsr, 1.01-1.31;
bootstrapped P value (pbootsr) ¼ .038). A reduced risk of progression
was observed for SLCO1B1-rs4149056, and for ABCG2-
rs2046134, on genes involved in steroid transport (SLCO1B1-
rs4149056 dominant model, AdjHR ¼ 0.54 [95%CIbootsr, 0.36-
0.80], pbootsr ¼ .002; ABCG2-rs2046134 dominant model,
AdjHR ¼ 0.62 [95%CIbootsr, 0.39-0.97], pbootsr ¼ .038). The
homozygous variant TT genotypes of FGFR4-rs351855 and of
XRCC3-rs861539 were associated with a higher risk of progression
compared with wild type or heterozygous patients (FGFR4-
rs351855 recessive model, AdjHR ¼ 1.85 [95%CIbootsr,
1.03-3.34], pbootsr ¼ .039; XRCC3-rs861539 recessive model,
AdjHR ¼ 1.72 [95%CIbootsr, 1.02-2.90], pbootsr ¼ .043).
To assess the role of the simultaneous presence of different risk
alleles, 0, 1, or 2 points were assigned to the 6 genotypes previ-
ously described and a risk score was generated grouping the 5
polymorphisms associated with shorter PFS. A point was assigned
to each genotype of the 5 polymorphisms according to its risk of
progression, as shown in Table 3: additive model: 0 points if
patients had 0 risk alleles, 1 point for 1 risk allele, 2 points for 2
risk alleles; dominant models: 0 points if patients had at least 1
protective allele, 1 point for 0 protective alleles; recessive models:
0 points if patients had 0 or 1 risk allele, and 1 point for 2 risk
alleles. According to the genotype of each polymorphism, patients
had a total score derived according to the sum of the assigned
points, ranging from 0 to 6. Patients were then aggregated into 4
risk groups: 0 to 1 risk points (n ¼ 26 patients), 2 risk points (n
¼ 84 patients), 3 risk points (n ¼ 111 patients), and 4 to 6 risk
points (n ¼ 75 patients).Figure 3A and Table 4 show PFS in the 4 groups of patients
stratified according to the risk score. As shown, patients in the 4 to 6
risk group performed worse than those in the 3, 2, and 0 to 1 groups
(log rank P ¼ .0002). Accordingly, the risk of progression increased
with the number of risk points: patients in the 4 to 6 risk group and
those in the 3 risk group had a significantly greater risk of
progression than patients in the 0 to 1 risk group (AdjHR for the
4-6 risk group ¼ 3.12 [95% CI, 2.18-4.48], P < .001; AdjHR for
the 3 risk group ¼ 2.01 [95% CI, 1.20-3.36], P ¼ .008). Even if
the difference was not statistically significant, the group of patients
carrying 2 risk points had a greater risk of progression than patients
with 0 to 1 risk points (AdjHR for the 2 risk group ¼ 1.39 [95%
CI, 0.88-2.20], P ¼ .149).
Patients with the highest score (4-6 risk points) exhibited the
lowest median PFS: 10.0 months (95% CI, 8.1-14.4 months),
whereas patients with the lowest score (0-1 risk points) showed a
median PFS of 26.3 months (95% CI, 15.9-39.0 months;
P ¼ .0002).
None of the germ line variants individually investigated was
significantly associated with OS. Nonetheless, the risk score allowed
a global stratification of patients according to OS with the same
trend (P ¼ .07) observed for PFS (Figure 3B). Intriguingly, by
comparing only the groups with the highest risk score (4-6 points)
versus the lowest risk score (0-1 points), the difference was signifi-
cant in the univariate and in the multivariate models (Table 4).
Discussion
In the modern armamentarium of the treatment of HRþ locally
advanced or MBC, AIs still retain a crucial role. However, although
a first stabilization of the tumor burden takes place in several locally
advanced or MBC patients treated with AIs, disease progression
almost always occurs, frequently after only a few months of treat-
ment. Prognostic or predictive biomarkers for exemestane outcome
are, hence, a clinical need.
Recently, somatic DNA variations have been described to affect
AI response during neoadjuvant treatment, but the role of germ line
variants in PFS and OS after first-line exemestane treatment remains
to be elucidated. A prospective multicenter study was designed to
identify germ line variants associated with PFS and OS in locally
advanced or MBC patients treated with first-line exemestane.
Polymorphic variants in genes involved in exemestane pharmaco-
kinetics and pharmacodynamics, hormone balance, DNA repair,
and cell signaling pathways were considered. Multivariate and
bootstrap analyses highlighted 5 polymorphisms as significantlyClinical Breast Cancer Month 2018 - 5
Figure 2 KaplaneMeier Estimates for Progression-Free Survival (PFS) According to 3 Polymorphisms in Hormone Balance Pathways:
(A) CYP19A1-rs10046, Additive Model (add), (B) SLCO1B1-rs4149056, Dominant Model (dom), and (C) ABCG2-rs2046134,
dom; and 2 Polymorphisms in DNA Repair and Cell Signaling Pathways: (D) FGFR4-rs351855, Recessive Model (rec), and (E)
XRCC3-rs861539, rec. Adjusted Hazard Ratio (AdjHR) and P Values Were Determined Using a Multivariate Cox Regression
and Bootstrap Analyses: CYP19A1-rs10046: AdjHR, 1.15 (95% CI Bootstrapped Value [bootsr], 1.01-1.31), P bootsr [ .038;
SLCO1B1-rs4149056: AdjHR, 0.54 (95% CI bootsr, 0.36-0.80), P bootsr, .002; ABCG2-rs2046134: AdjHR, 0.62 [95% CI bootsr, 0.39-
0.97], P bootsr[ .038; FGFR4-rs351855: AdjHR, 1.85 (95% CI bootsr, 1.03-3.34), P bootsr[ .039; XRCC3-rs861539: AdjHR, 1.72
(95% CI bootsr, 1.02-2.90), P bootsr [ .043). “D” Indicates Censored
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Table 3 Points Attributed to the Risk Genotypes Associated With PFS and OS
Polymorphism Patient’s Genotype Type of Allele Risk Points Attributed Genetic Model
CYP19A1-rs10046 TT C ¼ risk allele 0 Additive
CYP19A1-rs10046 TC 1
CYP19A1-rs10046 CC 2
SLCO1B1-rs4149056 TC or CC C ¼ protective allele 0 Dominant
SLCO1B1-rs4149056 TT 1
ABCG2-rs2046134 AA or AG A ¼ protective allele 0 Dominant
ABCG2-rs2046134 GG 1
FGFR4-rs351855 TC or CC T ¼ risk allele 0 Recessive
FGFR4-rs351855 TT 1
XRCC3-rs861539 TC or CC T ¼ risk allele 0 Recessive
XRCC3-rs861539 TT 1
Abbreviations: OS ¼ overall survival; PFS ¼ progression-free survival.
Sara Gagno et alassociated with PFS: CYP19A1-rs10046, XRCC3-rs861539,
ABCG2-rs2046134, SLCO1B1-rs4149056, and FGFR4-rs351855.
The main findings reported in the literature regarding these poly-
morphisms are summarized in Supplemental Table 2 in the online
version.
Cytochrome P450 19A1 codes for the aromatase enzyme, the
target of exemestane. Aromatase catalyzes the conversion of C19Figure 3 KaplaneMeier Curves for (A) Progression-Free
Survival (PFS) and (B) Overall Survival (OS) According
to the Genetic Risk Score. Patients Were Divided Into
4 Groups On the Basis of the Number of Risk Points.
KaplaneMeier Log Rank Survival Analysis (2-Sided)
Was Used to Calculate P Values (PFS, P ¼ .0002; OS,
P ¼ .07). “j” Indicates Censoredandrogens into C18 estrogens, a critical step in estrogen biosyn-
thesis, inhibited by exemestane. Extensive research has been done to
investigate the role of CYP19A1 polymorphisms in hormone ther-
apy efficacy, but data produced so far are contradictory. A recent
meta-analysis26 described an association between the CYP19A1-
rs4646 polymorphism and time to progression in AI-treated BC
patients. The authors concluded that the effect of CYP19A1 poly-
morphisms on clinical outcomes were most often detected in in-
dividual studies, underling the necessity of performing prospective
validation studies. Our prospective study failed to confirm any as-
sociation between rs4646 and PFS. The only CYP19A1 poly-
morphism associated with PFS was the rs10046, a 30 untranslated
region variation, which has a low level of linkage disequilibrium
with rs4646 (r2 ¼ 0.39 in the European 1000G phase 1 popula-
tion). A recent work of Magnani et al27 highlighted how AI-resistant
patients show acquired CYP19A1 amplification in their recurrent
tumor. Amplification of this gene also occurred in vitro in AI-
resistant models, showing a higher aromatase activity. In light of
these results it seems that CYP19A1 amplification at the tumor level
might be more important than germ line variations in determining
the response to exemestane.
It is well known that genotoxic estrogen metabolites might cause
DNA damage.28 XRCC3 is involved in the DNA synthesis and repair
pathways. In our study, patients carrying the XRCC3-rs861539TT
genotype (241 Met/Met) had an increased risk of progression
compared with the TC and CC genotypes. The 241Met/Met variant
was associated with a decreasedDNA repair capacity29 and it has been
considered a biomarker of survival in MBC patients treated with
DNA-damaging chemotherapy.30 Similarly, patients carrying the
XRCC3-rs861539TT genotype might be unable to repair genotoxic
estrogen metabolite damage or other genotoxic insults, allowing cell
proliferation and cancer progression.31
Steroid transporters have a critical role in tumor response to
hormone therapy in BC.32 In our study we observed that poly-
morphisms in 2 genes (ABCG2 and SLCO1B1) encoding for steroid
transporters, were associated with an increased PFS. Patients
carrying at least 1 variant allele of either ABCG2-rs2046134 (A) or
SLCO1B1-rs4149056 (C-174Ala) had a significantly reduced risk of
progression compared with the wild type alleles. ABCG2 and
SLCO1B1 genes encode for BC resistance protein (BCRP) andClinical Breast Cancer Month 2018 - 7
Table 4 Median PFS and OS According to the Risk Score: Univariate and Multivariate Analysis
Risk Points
Median Survival
(95% CI), Months Log Rank P
Univariate Multivariate
HR (95% CI) P AdjHR (95% CI) P
PFS
0-1 26.3 (15.9-39.0) .0002 Ref Ref
2 22.3 (13.2-30.3) 1.32 (0.98-1.79) .07 1.40 (0.89-2.20) .149
3 13.4 (9.7-17.9) 1.80 (1.21-2.66) .004 2.00 (1.20-3.36) .008
4-6 10.0 (8.1-14.4) 2.54 (1.90-3.39) <.001 3.12 (2.18-4.48) <.001
OS
0-1 63.0 (43.9-not reached) .07 Ref Ref
2 58.9 (48.5-69.8) 1.44 (0.79-2.63) .233 1.34 (0.77-2.34) .300
3 48.3 (36.5-65.1) 1.72 (0.85-3.47) .131 1.77 (0.97-3.20) .061
4-6 38.9 (34.3-45.8) 2.28 (1.61-4.50) .017 2.41 (1.22-4.79) .012
Significant results are shown in bold text.
Abbreviations: AdjHR ¼ adjusted hazard ratio; HR ¼ hazard ratio; OS ¼ overall survival; PFS ¼ progression-free survival; Ref ¼ reference category.
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8 - Cliorganic anion-transporting polypeptide 1B1, respectively. These are
transporters also involved in the detoxification process of xenobiotic
and antineoplastic drugs.33,34 Very recently the SLCO1B1-
rs4149056 polymorphism has been associated with exemestane
pharmacokinetics. In a study involving few healthy volunteers,
women carrying at least 1 variant C allele showed a statistically
significant higher area under the time/concentration curve for
exemestane and its metabolite.35 Moreover, SLCO1B1-rs4149056
is a predictor of statins and 3-hydroxy-3-methyl-glutaryl-coenzyme
A reductase inhibitors disposition. Intriguingly, in our study, pa-
tients carrying at least 1 C allele had a prolonged PFS, probably as a
result of an increased drug exposure because of the effect of this
polymorphism. Regarding BCRP, at present, no data have been
reported on its effect on exemestane. However, it must be consid-
ered that exemestane and its metabolites share similar chemical
structures of the steroidal derivatives that are BCRP substrates.
The FGFR is a transmembrane tyrosine kinase receptor involved
in multiple biological processes, including cell proliferation, differ-
entiation, and apoptosis. Previous reports indicate that endocrine
resistance involves a cross-talk between growth factor pathways and
estrogen signaling.9,36 In BC, aberrant FGFR signaling, including
the FGFR4-rs351855 polymorphism (Gly388Arg), has been
involved in tumor progression and resistance to tamoxifen.37
In vitro reports showed an increased motility of mammary cells
with 388 Arg/Arg variant and also an increased extracellular matrix
degradation.37 According to this detrimental effect, we observed
that patients carrying FGFR4-rs351855 homozygous variant geno-
type (TT-388 Arg/Arg) were at a significantly increased risk of
progression compared with TC and CC genotypes.
The 6 risk genotypes significantly associated with a shorter PFS
(CYP19A1-rs10046TC/CC, SLCO1B1-rs4149056TT, ABCG2-
rs2046134GG, FGFR4-rs351855TT, and the XRCC3-
rs861539TT) were combined into a genetic risk score, allowing the
definition of 4 risk groups of patients. As a result, we obtained a
better stratification of patients according to their PFS, with a sub-
stantial improvement in the predictive ability of the score compared
with the individual polymorphisms. Patients carrying 2, 3, and 4 tonical Breast Cancer Month 20186 risk points had a 40%, 100%, and more than 200% increased risk
of progression, respectively, than patients with 0 to 1 risk points.
We observed an overall not statistically significant trend for the
association of OS with the risk score. The fact that we have not
taken into account treatments after progression, which can affect
OS, might explain this lack of significance. However, when
considering only the groups with the highest and lowest risk points
(4-6 vs. 0-1), the difference in OS became statistically significant,
indicating that this score might be helpful in OS prediction for at
least these extreme groups of patients, allowing identification of the
ones at the highest and the lowest risk of death.
Another limitation of this study is that an external validation
cohort is missing, due to the difficulty of finding a prospective study
with similar characteristics. However, the bootstrap analysis, con-
sisting in the replication of the findings by drawing 1000 samples
from the original data set, allowed an internal assessment of
reproducibility. Moreover, this study could evaluate only the
prognostic role of the germ line polymorphisms. The assessment of
the predictive value of the biomarkers could not be established,
because of the lack of a control arm with patients not treated with
exemestane.
To the best of our knowledge, this is the largest prospective study
specifically designed to evaluate pharmacogenetic biomarkers of PFS
and OS in patients treated with exemestane. In addition, the long
follow-up (median: almost 3 years) is another point of strength of
the study.
Conclusion
Our findings show that germ line polymorphisms in hormone
balance, drug activity, DNA replication and repair, as well as in
signaling pathways are associated with PFS and OS of
exemestane-treated patients. The joint effect of polymorphisms
from multiple pathways included in a multifactorial genetic score
might better define groups of patients with different prognoses.
Replication studies, in external cohorts of patients, are none-
theless required to finally ascertain the clinical utility of these
markers.
Sara Gagno et alClinical Practice Points
 Several studies investigated the role of genetic variations in genes
involved in exemestane pharmacokinetics, pharmacodynamics,
and hormone balance pathways. Even if several associations have
been found with exemestane outcome, no consensus has been
reached on polymorphisms to be translated into clinical practice
as predictive or prognostic biomarkers.
 This study highlighted 5 polymorphisms on genes involved in AI
pathways and also in DNA repair pathways. The combination of
these 5 polymorphisms into a score allow better stratification of
patients according to their PFS and OS.
 The use of this pharmacogenetic score might help, through a
simple blood test, to identify patients who might require a
different or more aggressive therapeutic approach because of their
higher risk of progression and/or death.Acknowledgments
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9.e1Supplemental DataSupplemental Table 1 List of the Analyzed Polymorphisms
Pathway Gene rsID Polymorp
Estrogen Synthesis CYP19A1 rs10046 T>C
Estrogen Synthesis CYP19A1 rs60271534 (TTTA) 7
Estrogen Synthesis CYP19A1 rs4646 C>A
Estrogen Synthesis CYP19A1 rs700519 C>T
Estrogen Synthesis CYP17A1 rs743572 A>G
Estrogen Activity ESR1 rs9340799 A>G
Estrogen Activity ESR1 rs2234693 T>C
Estrogen Activity ESR2 rs1256049 G>A
Estrogen Activity ESR2 rs4986938 G>A
Estrogen Activity PRDM2 rs2308040 D>I
Estrogen Metabolism COMT rs4680 A>G
Estrogen Metabolism CYP1B1 rs1056836 C>G
Estrogen Metabolism UGT1A1 rs8175347 (TA) 5-
Estrogen Metabolism CYP2C9 rs1799853 C>T
Exemestane Metabolism CYP3A4 rs2740574 A>G
Exemestane Metabolism CYP3A5 rs776746 G>A
Steroids Transport, MDR ABCB1 rs10276036 T>C
Steroids Transport, MDR ABCB1 rs2235013 A>G
Steroids Transport, MDR ABCB1 rs2235015 G>T
Steroids Transport, MDR ABCB1 rs2235033 C>T
Steroids Transport, MDR ABCB1 rs3213619 T>C
Steroids Transport, MDR ABCB1 rs3842 A>G
Steroids Transport, MDR ABCC1 rs2074087 G>C
Steroids Transport, MDR ABCC1 rs212088 C>T
Steroids Transport, MDR ABCC1 rs2230671 G>A
Steroids Transport, MDR ABCC1 rs35587 T>C
Steroids Transport, MDR ABCC1 rs35588 A>G
Steroids Transport, MDR ABCC1 rs35605 C>T
Steroids Transport, MDR ABCC1 rs3765129 C>T
Steroids Transport, MDR ABCC1 rs4148356 G>A
Steroids Transport, MDR ABCC1 rs60782127 G>T
Biliary Transport, MDR ABCC2 rs17216177 T>C
Biliary Transport, MDR ABCC2 rs2002042 C>T
Biliary Transport, MDR ABCC2 rs2273697 G>A
Biliary Transport, MDR ABCC2 rs3740066 G>A
Biliary Transport, MDR ABCC2 rs4148396 C>T
Biliary Transport, MDR ABCC2 rs717620 G>A
Biliary Transport, MDR ABCC2 rs8187710 G>A
Steroids Transport, BCRP ABCG2 rs2046134 G>A
Steroids Transport, BCRP ABCG2 rs2231142 C>A
Steroids Transport, BCRP ABCG2 rs2622604 C>T
Steroids Transport, BCRP ABCG2 rs3219191 D>I
Steroids Transport SLCO1B1 rs4149056 T>C
Cell Cycle, DNA Repair ATM rs1801516 G>A
Cell Cycle, DNA Repair CDKN1A rs1801270 C>A
Cell Cycle, DNA Repair MDM4 rs4245739 A>C
Cell Cycle, Signaling FGFR4 rs351855 C>T
DNA Repair APEX1 rs1130409 T>G
DNA Repair MSH6 rs3136228 T>G
DNA Repair OGG1 rs1052133 C>G
- Clinical Breast Cancer Month 2018hism Patients, n Variant Allele %
302 C 48
-13 302 L 50
302 A 29
302 T 3
302 G 42
302 G 38
302 C 46
302 A 2
302 A 41
302 I 37
302 A 50
302 G 44
8 300 L 35
301 T 11
302 G 2
302 A 5
299 C 43
300 G 48
299 T 19
299 T 48
300 C 4
298 G 14
301 C 17
300 T 16
302 A 23
299 C 33
302 G 31
302 T 19
299 T 14
302 A 0
302 T 1
302 C 7
302 T 23
301 A 19
302 A 37
302 T 38
302 A 18
302 A 7
299 A 5
302 A 9
299 T 22
299 I 45
300 C 16
302 A 14
302 A 7
299 C 30
301 T 27
302 G 46
301 G 37
302 G 21
Supplemental Table 1 Continued
Pathway Gene rsID Polymorphism Patients, n Variant Allele %
DNA Repair ERCC5 rs17655 C>G 302 G 22
DNA Repair XRCC1 rs1799782 C>T 302 T 6
DNA Repair XRCC1 rs25487 G>A 302 A 33
DNA Repair XRCC1 rs25489 G>A 300 A 6
DNA Repair XRCC3 rs1799794 A>G 302 G 22
DNA Repair XRCC3 rs1799796 A>G 301 G 27
DNA Repair XRCC3 rs861539 C>T 302 T 42
DNA Repair, NER ERCC1 rs11615 T>C 302 C 40
DNA Repair, NER ERCC1 rs3212986 G>T 302 T 27
DNA Repair, NER ERCC2 rs13181 T>G 301 G 44
DNA Synthesis ATIC rs2372536 C>G 302 G 36
DNA Synthesis, Folate Cycle FOLR1 rs2071010 G>A 302 A 6
DNA Synthesis, Folate Cycle FOLR1 rs9282688 C>T 302 T 2
DNA Synthesis, Folate Cycle FPGS rs10106 A>G 302 G 37
DNA Synthesis, Folate Cycle GGH rs11545078 C>T 301 T 11
DNA Synthesis, Folate Cycle MTHFD1 rs2236225 C>T 302 T 43
DNA Synthesis, Folate Cycle MTHFR rs1801131 A>C 302 C 32
DNA Synthesis, Folate Cycle MTR rs1805087 A>G 301 G 19
DNA Synthesis, Folate Cycle MTRR rs1801394 A>G 301 G 49
DNA Synthesis, Folate Cycle SHMT1 rs2273029 C>T 302 T 25
DNA Synthesis, Folate Cycle TYMS rs16430 I>D 302 D 38
DNA Synthesis, Folate Cycle TYMS rs2790 A>G 302 G 25
DNA Synthesis, Folate Cycle TYMS rs699517 C>T 301 T 38
TP53 Signaling TP53 rs1042522 G>C 302 C 29
List of the analyzed polymorphisms with the pathway they are involved in, the number of patients genotyped, and the frequencies of the variant alleles. Underlined, polymorphisms in linkage
disequilibrium, according to r2 threshold ¼ 0.8. For the polymorphisms CYP19A1-rs60271534 and for UGT1A1-rs8175347 alleles were associated into 2 groups, long (L) and short (S) alleles: L  7
TTTA, S < 7 TTTA repeats, and L ¼ 7-8 TA, S ¼ 5-6 TA repeats, respectively.
Abbreviations: BCRP ¼ breast cancer resistance protein; D ¼ deletion; I ¼ insertion; MDR ¼ multidrug resistance; NER ¼ nucleotide excision repair; rsID ¼ reference single-nucleotide poly-
morphism identification number; TP53 ¼ tumor protein 53.
Sara Gagno et al
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Supplemental Table 2 Role, Function, and Associations Found in the Literature for the Polymorphisms Significantly Associated With PFS
Gene
SNP (Amino Acid
Change) Location
Predicted or
Functional Role Cancer Type Treatment End Point Patient n
Association With
the Variant
Allele or Gene Reference
CYP19A1 rs10046 30 UTR Y Estrogen levels Healthy subjects None Estrogen levels 1975 Y Estrogen levels
BC Adjuvant LET Estrogen levels 204 None 1
BC NR DFS Total 1257, premenopausal
439
[ DFS (premenopausal) 2
BC TAM and/or LET Bone AEs 4861 [ Bone AE risk 3
BC NR BC Risk 522 Cases/1221 controls [ BC risk 4
BC NR BC Risk 20,098 (meta-analysis) None 4
BC NR BC Risk 1164 Cases/2111 controls None 5
BC LET; ANA TTP 67,272 None 6,7
BC Neoadjuvant LET Response 95 None 8
BC ANA, LET, EXE TTP, AEs NR None 9
BC AIs OS 53 [ OS with WT allele 10
SLCO1B1 rs4149056 (Val174Ala) Exonic Y Transport activity Healthy subjects None Activity NR Y Transport activity 11
BC cell line NA Activity NA Y Transport activity 12
BC TAM OS 296 Y OS 13
FGFR4 rs351855 (Gly388Arg) Exonic [ Tumor cell motility BC cell line NA Cell motility NA [ Tumor cell motility 14
BC None, CMF, and/or TAM DFS 84 Y DFS 14
PC cell line NA Tumor invasion NA [ ECM degradation 15
BC transgenic mouse NA BC progression NA [ Tumor progression 16
Multiple, including BC NA OS 2537 (Pooled analysis) Y OS 10
BC Adjuvant CMF and/or
TAM
DFS/OS 372 Y DFS/OS 17
BC TAM CB/PFS 285 Y CB/DFS 18
ABCG2 rs2046134 Intronic Transcription factor
binding site (predicted)a
Tissue from healthy
donors/GIST
AI-resistant cells/
xenograft tumors
Imatinib
LET, EXE
Functional effect
AI resistance
44 þ 60 þ 28 Tissues/82
GIST patients
[ Protein expression
Involvement of ABCG2 in
AI resistance
ConSite19-21,a
XRCC3 rs861539 (Thr241Met) Exonic Possibly damaging
(predicted)b
GIST Imatinib OS 81 Y OS Polyphen-222,b
BC Anthracyclines OS 150 [ OS 23
BC NR BC risk 70 Cases/70 controls BC risk 24
BC NR BC risk 19,575 cases/21,
125 controls
[ BC risk 25
The literature analysis was focused on the identification of the role of the SNPs with cancer risk, toxicities, patients’ prognosis, and cellular transformation. In case of no functional data available in literature, we referred to the results obtained with bioinformatic analysis exploiting
ConSite (http://compbio.cs.queensu.ca/F-SNP) and PolyPhen (http://genetics.bwh.harvard.edu/ggi/pph2/e8dbeaa52a8642d83df5575a0830d51a00e71f38/5502954.html).
Abbreviations: AE ¼ adverse event; AI ¼ aromatase inhibitor; ANA ¼ anastrozole; BC ¼ breast cancer; CB ¼ clinical benefit; CMF ¼ cyclophosphamide/methotrexate/fluorouracil; DFS ¼ disease free survival; ECM ¼ extracellular matrix; EXE ¼ exemestane; GIST ¼
gastrointestinal stromal tumor; LET ¼ letrozole; OS ¼ overall survival; PC ¼ prostate cancer; PFS ¼ progression-free survival; SNP ¼ single nucleotide polymorphism; TAM ¼ tamoxifen; TTP ¼ time to progression; UTR ¼ untranslated region; WT ¼ wild type.
aPredicted by ConSite.
bPredicted by PolyPhen-2.
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